首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1544588

視網膜疾病治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Retinal Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月03日 | 出版商:

Global Market Insights Inc. | 英文 175 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在視網膜疾病盛行率不斷上升和治療技術進步的推動下，2024年至2032年全球視網膜疾病治療市場的複合年成長率預計將達到9.6%。由於人口老化和糖尿病等慢性病發病率的上升，黃斑部病變和糖尿病視網膜病變等視網膜疾病變得越來越常見。此外，研究和開發方面不斷增加的資金和努力也支持了市場。

例如，2024 年 7 月，抗盲基金會為視網膜疾病研究提供了一項為期三年、價值 150 萬美元的新撥款。凱斯西儲大學醫學院眼科和視覺科學副教授松山茂美 (Shigemi Matsuyama) 被指派研究一種潛在的突破性口服藥物。

對有效和創新治療方案的需求正在推動市場成長。此外，藥物傳遞系統和治療創新的進步正在增強視網膜疾病治療的功效，支持市場擴張。

整個視網膜疾病治療行業根據類型、劑型、配銷通路和地區進行分類。

黃斑部病變，特別是老年黃斑部病變（AMD），預計將成為視網膜疾病治療市場的主要成長動力。 AMD 是老年人視力喪失的主要原因，推動了對有效治療的巨大需求。黃斑部病變治療市場包括抗 VEGF 療法和新興基因療法。抗 VEGF 治療目前使用最廣泛，並已證明在減緩疾病進展和提高視力方面具有顯著效果。新療法的不斷開發和治療方案的改進將促進該領域的市場成長。

以玻璃體內注射、眼藥水和植入物等劑型分類的眼部解決方案領域將大幅成長。玻璃體內注射由於直接將藥物輸送到玻璃體中而受到重視，確保了視網膜疾病的更高的生物利用度和療效。眼藥水和植入物在治療領域也發揮著至關重要的作用，為患者提供友善的選擇和持續的藥物釋放。藥物傳遞技術的發展和創新劑型的引入正在推動眼部解決方案在視網膜疾病治療市場的採用。

2024年至2032年，歐洲視網膜疾病治療市場將顯著成長。在有利的監管框架和促進醫療創新的政府措施的支持下，歐洲國家處於採用先進治療方案的前沿。領先的製藥和生物技術公司的存在進一步增強了市場，持續的研究和開發工作推動了針對視網膜疾病的新的和改進的療法的推出。

產業生態系統分析
產業影響力
- 成長動力
  - 糖尿病盛行率增加
  - 老年人口不斷增加
  - 技術進步
  - 提高認知和篩檢計劃
- 產業陷阱與挑戰
  - 治療費用高
  - 副作用和安全問題
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
2023 年定價分析
- 按地區
- 按關鍵人物
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
糖尿病視網膜病變
黃斑部病變
- 乾性黃斑部病變
- 濕性黃斑部病變
糖尿病黃斑水腫
視網膜靜脈阻塞
其他類型

第 6 章：市場估計與預測：按劑型，2021 - 2032

主要趨勢
膠囊和片劑
眼藥水
眼睛解決方案
凝膠
藥膏

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AbbVie Inc.
Alimera Sciences, Inc.
Alcon, Inc.
Bayer AG
Biogen Inc.
Bausch Health Companies
F. Hoffmann-La Roche Ltd.
Graybug Vision, Inc.
Merck and Co., Inc.
Novartis AG
Ophthotech Corporation
Pfizer, Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceuticals Co. Ltd.
Takeda Pharmaceutical Company Limited

簡介目錄

Product Code: 10121

Global Retinal Disorder Treatment Market is poised to attain a 9.6% CAGR from 2024 to 2032, driven by the increasing prevalence of retinal disorders and advancements in treatment technologies. Retinal disorders, such as macular degeneration and diabetic retinopathy, are becoming more common due to an aging population and rising rates of chronic conditions like diabetes. Additionally, the increasing funding and efforts in research and development support the market.

For instance, in July 2024, a new three-year, $1.5 million grant from the Foundation Fighting Blindness was granted for retinal disorder research. Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at Case Western Reserve University School of Medicine, was assigned to investigate a potentially groundbreaking oral drug.

The demand for effective and innovative treatment options is fueling market growth. Additionally, advancements in drug delivery systems and therapeutic innovations are enhancing the efficacy of retinal disorder treatments, supporting market expansion.

The overall Retinal Disorder Treatment Industry is classified based on the type, dosage form, distribution channel, and region.

Macular degeneration, particularly age-related macular degeneration (AMD), is anticipated to be a major growth driver within the Retinal Disorder Treatment Market. AMD is a leading cause of vision loss among the elderly, driving significant demand for effective treatments. The market for macular degeneration treatments includes both anti-VEGF therapies and emerging gene therapies. Anti-VEGF treatments are currently the most widely used and have demonstrated substantial effectiveness in slowing disease progression and improving visual acuity. The continuous development of novel therapies and improved treatment protocols will boost market growth in this segment.

The eye solutions segment, categorized by dosage forms such as intravitreal injections, eye drops, and implants, will showcase substantial growth. Intravitreal injections are gaining prominence due to their direct delivery of drugs into the vitreous body, ensuring higher bioavailability and efficacy for retinal disorders. Eye drops and implants also play a crucial role in the treatment landscape, offering patient-friendly options and sustained drug release. The evolution of drug delivery technologies and the introduction of innovative dosage forms are driving the adoption of eye solutions in the retinal disorder treatment market.

Europe will experience significant growth in the Retinal Disorder Treatment Market from 2024 to 2032. The region benefits from a robust healthcare infrastructure, high investment in medical research, and a rising prevalence of retinal disorders. European countries are at the forefront of adopting advanced treatment options, supported by favorable regulatory frameworks and government initiatives promoting healthcare innovation. The presence of leading pharmaceutical and biotechnology companies further strengthens the market, with ongoing research and development efforts driving the introduction of new and improved therapies for retinal disorders.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of diabetes
  - 3.2.1.2 Rising geriatric population
  - 3.2.1.3 Technological advancements
  - 3.2.1.4 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment cost
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diabetic retinopathy
5.3 Macular degeneration
- 5.3.1 Dry macular degeneration
- 5.3.2 Wet macular degeneration
5.4 Diabetic macular edema
5.5 Retinal vein occlusion
5.6 Other types

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Capsules and tablets
6.3 Eye drops
6.4 Eye solutions
6.5 Gels
6.6 Ointments

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa